Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.